Tuesday, February 6, 2018
After 25 years of anticipation, the first gene therapy product was approved in 2017. This is an amazing time in gene therapy and uniQure is a leader in the field. uniQure’s Chief Executive Officer, Matt Kapusta, talked about creating transformative therapies for patients with rare diseases and the process of bringing innovative cures to market.
Matt Kapusta, CEO, uniQure
Mr. Matthew Kapusta joined uniQure as their chief financial officer in January 2015 and was elected to their Management Board at the 2015 annual general meeting. In December 2016 he was appointed uniQure’s chief executive officer.
Prior to joining uniQure, Mr. Kapusta was Senior Vice President at AngioDynamics from 2011 to 2014, responsible for corporate development, strategic planning and national accounts. Prior to AngioDynamics, he served as Vice President, Finance for Smith & Nephew Orthopaedics. Mr. Kapusta's career also includes more than a decade of investment banking experience focused on emerging life sciences companies. Mr. Kapusta was Managing Director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens, and PaineWebber.
Mr. Kapusta holds a Master of Business Administration from New York University's Stern School of Business, a Bachelor of Business Administration from University of Michigan's Ross School of Business and earned his Certified Public Accountant license in 1996 while at Ernst & Young.